Drug name - Epclusa
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(5 years from now) | |
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(5 years from now) | |
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(5 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(6 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(6 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(7 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(8 years from now) | |
| US8921341 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(10 years from now) | |
| US8940718 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(10 years from now) | |
| US8575135 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(10 years from now) | |
| CN102906102A | GILEAD SCIENCES INC | Stereoselective Synthesis Of Phosphorus-Containing Active Matter |
Nov, 2015
(6 years ago) | |
| CN104292256A | GILEAD SCIENCES INC | N - [(2 ' R) -2 '--2 '--2 ' - Methyl-Beta-Phenyl - -5 ' - Uridine Acyl] -L - Alanine 1-Methyl Ethyl Ester And Preparation Method Thereof |
Nov, 2018
(3 years ago) | |
| CN105198949A | GILEAD SCIENCES INC | N-[(2 ' R)-2 '--2 '-Fluorin-2 '-De-Oxide Methyl-[Beta]-Phenyl-5 '-Uridine Acyl]-L-Alanine 1-Methyl Ethyl Ester And Its Preparation Method |
Dec, 2019
(2 years ago) | |
| CN105085592B | GILEAD SCIENCES INC | N - [(2 ' R) - 2 ' - Deoxy-2 ' - Fluorine-2 ' - Methyl-Beta-Phenyl-5 ' - Uridine Acyl] -L - Lactamine 1-Methyl Ethyl Ester And Its Preparation Method |
May, 2030
(7 years from now) | |
| CN102459299B | GILEAD SCIENCES INC | N- [ (2 ' R) -2 ' -Deoxy-2 ' -Fluoro-2 ' -Methyl-P-Phenyl-5 ' -Uridylyl] -L-Alanine 1-Methylethyl Ester And Process For Its Production |
May, 2030
(7 years from now) | |
| CN105085592A | GILEAD SCIENCES INC | N-[(2 ' R)-2 '--2 '-Fluorin-2 '-De-Oxide Methyl-[Beta]-Phenyl-5 '-Uridine Acyl]-L-Alanine 1-Methyl Ethyl Ester And Preparation Method Thereof |
May, 2030
(7 years from now) | |
| CN102459299A | GILEAD SCIENCES INC | N- [ (2 ' R) -2 ' -Deoxy-2 ' - Fluoro-2'-Methyl-P-Phenyl-5 ' -Uridylyl] -L-Alanine-1-Methylethyl Ester Process For Its Production |
May, 2030
(7 years from now) | |
| CN104017020B | GILEAD SCIENCES INC | Nucleoside Phosphoramidate |
Mar, 2031
(8 years from now) | |
| CN104017020A | GILEAD SCIENCES INC | Stereoselective Synthesis Of Phosphorus Containing Actives |
Mar, 2031
(8 years from now) | |
| CN105837584A | GILEAD SCIENCES INC | Condensed Imidazolyl-Imidazole As Antiviral Compound |
Nov, 2032
(10 years from now) | |
| CN105837584B | GILEAD SCIENCES INC | Condensation Of Imidazole Imidazole As Antivirus Compound |
Nov, 2032
(10 years from now) | |
| CN103328480B | GILEAD SCIENCES INC | Condensed Imidazolyl-Imidazole As Antiviral Compound |
Nov, 2032
(10 years from now) | |
| CN103328480A | GILEAD SCIENCES INC | A Imidazole Imidazole For Condensation Of Antiviral Composition |
Nov, 2032
(10 years from now) | |
| IN346815B | GILEAD SCIENCES INC | N-[ (2&Amp;Apos;R) -2&Amp;Apos; Deoxy-2&Amp;Apos;- Fluoro-2&Amp;Apos;-Methyl-Pphenyl- 5&Amp;Apos;-Uridylyl] -L-Alanine 1- Methylethyl Ester And Process For Its Production |
May, 2030
(7 years from now) | |
| EP2203462B1 | GILEAD SCIENCES INC | Nucleoside Phosphoramidate Prodrugs |
Jul, 2020
(2 years ago) | |
| EP2203462A2 | GILEAD SCIENCES INC | Nucleoside Phosphoramidate Prodrugs |
Jul, 2020
(2 years ago) | |
| EP2826784B1 | GILEAD SCIENCES INC | Composition Comprising A Hcv Ns3 Protease Inhibitor And A Phosphoramidate Prodrug Of 2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Nucleoside |
Mar, 2028
(5 years from now) | |
| EP2826784A1 | GILEAD SCIENCES INC | Composition Comprising A Hcv Ns3 Protease Inhibitor And A Phosphoramidate Prodrug Of 2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Nucleoside |
Mar, 2028
(5 years from now) | |
| EP2913337A1 | GILEAD SCIENCES INC | Process For The Production Of Sofosbuvir |
May, 2030
(7 years from now) | |
| EP2432792A1 | GILEAD SCIENCES INC | And Process For The Preparation Of N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-P-Phenyl-5'-Uridylyl]-L-Alanine 1-Methylethyl Ester |
May, 2030
(7 years from now) | |
| EP3321275B1 | GILEAD SCIENCES INC | Crystalline Form Of Sofosbuvir |
May, 2030
(7 years from now) | |
| EP3321275A1 | GILEAD SCIENCES INC | Crystalline Form Of Sofosbuvir |
May, 2030
(7 years from now) | |
| EP2432792B1 | GILEAD SCIENCES INC | And Process For The Preparation Of N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-P-Phenyl-5'-Uridylyl]-L-Alanine 1-Methylethyl Ester |
May, 2030
(7 years from now) | |
| EP2913337B1 | GILEAD SCIENCES INC | Process For The Production Of Sofosbuvir |
May, 2030
(7 years from now) | |
| EP2752422A1 | GILEAD SCIENCES INC | Stereoselective Synthesis Of Phosphorus Containing Actives |
Mar, 2031
(8 years from now) | |
| EP3290428B1 | GILEAD SCIENCES INC | Tablet Comprising Crystalline (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1 (2H)-Yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-Yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate |
Mar, 2031
(8 years from now) | |
| EP2552930B1 | GILEAD SCIENCES INC | Crystalline (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1-(2H)-Yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-Yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate |
Mar, 2031
(8 years from now) | |
| EP2552931A2 | GILEAD SCIENCES INC | Stereoselective Synthesis Of Phosphorus Containing Actives |
Mar, 2031
(8 years from now) | |
| EP2552931B1 | GILEAD SCIENCES INC | Stereoselective Synthesis Of Phosphorus Containing Actives |
Mar, 2031
(8 years from now) | |
| EP2609923A2 | GILEAD SCIENCES INC | Process For The Crystallisation Of (S)-Isopropyl 2-(((S)-(Perfluorophenoxy)(Phenoxy)Phosphoryl)Amino)Propanoate |
Mar, 2031
(8 years from now) | |
| EP2552930A2 | GILEAD SCIENCES INC | Crystalline (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1-(2H)-Yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-Yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate |
Mar, 2031
(8 years from now) | |
| EP2609923A3 | GILEAD SCIENCES INC | Nucleoside Phosphoramidates |
Mar, 2031
(8 years from now) | |
| EP3290428A1 | GILEAD SCIENCES INC | Tablet Comprising Crystalline (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1 (2H)-Yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-Yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate |
Mar, 2031
(8 years from now) | |
| EP2752422B1 | GILEAD SCIENCES INC | Stereoselective Synthesis Of Phosphorus Containing Actives |
Mar, 2031
(8 years from now) | |
| EP2609923B1 | GILEAD SCIENCES INC | Process For The Crystallisation Of (S)-Isopropyl 2-(((S)-(Perfluorophenoxy)(Phenoxy)Phosphoryl)Amino)Propanoate |
Mar, 2031
(8 years from now) | |
| EP2640719B1 | GILEAD SCIENCES INC | Antiviral Compounds |
Nov, 2031
(9 years from now) | |
| EP2640719A2 | GILEAD SCIENCES INC | Antiviral Compounds |
Nov, 2031
(9 years from now) | |
| EP3431477A1 | GILEAD SCIENCES INC | Condensed Imidazolylimidazoles As Antiviral Compounds |
Nov, 2032
(10 years from now) | |
| EP2635588A1 | GILEAD SCIENCES INC | Condensed Imidazolylimidazoles As Antiviral Compounds |
Nov, 2032
(10 years from now) | |
| EP2907816A1 | GILEAD SCIENCES INC | Condensed Imidazolylimidazoles As Antiviral Compounds |
Nov, 2032
(10 years from now) | |
| EP3431477B1 | GILEAD SCIENCES INC | Condensed Imidazolylimidazoles As Antiviral Compounds |
Nov, 2032
(10 years from now) | |
| EP2907816B1 | GILEAD SCIENCES INC | Condensed Imidazolylimidazoles As Antiviral Compounds |
Nov, 2032
(10 years from now) | |
| EP2635588B1 | GILEAD SCIENCES INC | Condensed Imidazolylimidazoles As Antiviral Compounds |
Nov, 2032
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(5 years from now) | |
|
US8334270
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US8735372
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US9085573
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
|
US8580765
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(6 years from now) | |
|
US7964580
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(6 years from now) | |
|
US8889159
(Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(6 years from now) | |
|
US8633309
(Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(6 years from now) | |
|
US9284342
(Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(8 years from now) | |
|
US8618076
(Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(8 years from now) | |
|
US8921341
(Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(10 years from now) | |
|
US8575135
(Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(10 years from now) | |
|
US8940718
(Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(10 years from now) | |
| US10086011 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(11 years from now) | |
| US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(11 years from now) | |
| US9757406 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(11 years from now) | |
|
US10086011
(Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
|
US11116783
(Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
|
US9757406
(Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
Treatment: For the treatment of hepatitis c
Dosage: PELLETS;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 150MG;37.5MG/PACKET | PELLETS;ORAL | Prescription |
| 200MG;50MG/PACKET | PELLETS;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.